#Cushings-Syndrome

2 stories

Clinical Trials June 15, 2026 · View digest

Crinetics Presents Full Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia and Interim ACTH-Dependent Cushing's Data at ENDO 2026

Crinetics Pharmaceuticals (Nasdaq: CRNX) presented on June 14 full results from its 12-week Phase 2 trial of atumelnant (CRN04894) in adults with classic congenital adrenal hyperplasia (CAH), the company's investigational once-daily oral ACTH receptor antagonist. The data showed rapid, substantial, and sustained statistically significant reductions in CAH disease biomarkers including androstenedione and 17-hydroxyprogesterone, with patients able to reduce glucocorticoid doses while maintaining androgen control. A separate Phase 1b/2a interim analysis in ACTH-dependent Cushing's syndrome showed that atumelnant rapidly lowered early-morning cortisol and normalized urinary free cortisol even at lower doses. Both programs are advancing toward Phase 3.

Clinical Trials May 15, 2026 · View digest

Crinetics Atumelnant Phase 2/3 Cushing's Syndrome Q2 2026 Initiation + Ohio University Growth Hormone Receptor Antagonist License

Crinetics also disclosed in the May 7 Q1 update that the company is on track to initiate a seamless Phase 2/3 trial of atumelnant in ACTH-dependent Cushing's syndrome in Q2 2026. The trial will assess efficacy in a broad population including Cushing's disease and ectopic ACTH syndrome. Atumelnant is also in Phase 3 for congenital adrenal hyperplasia. Separately, Crinetics announced an exclusive license agreement with Ohio University to develop an early-preclinical growth hormone receptor antagonist (GHRA) for acromegaly — a mechanism complementary to paltusotine's SST2 agonism that would compete in the same indication once both reach market.